Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature
- PMID: 35646510
- PMCID: PMC9142216
- DOI: 10.1055/s-0042-1749389
Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature
Abstract
Clinically silent double pituitary adenomas consisting of corticotroph and somatotroph cells are an exceedingly rare clinical finding. In this report, we present the case of a 28-year-old man with a 1-year history of recurrent headaches. Imaging revealed a 2.1 (anterior-posterior) × 2.2 (transverse) × 1.3 (craniocaudal) cm pituitary adenoma invading into the left cavernous sinus and encasing the left internal carotid artery. Endoscopic transnasal resection was performed without complications. Immunohistochemical staining revealed a double adenoma consisting of distinct sparsely granulated somatotroph and densely granulated corticotroph cells that were positive for growth hormone and adrenocorticotropic hormone, respectively. K i -67 index labeling revealed a level of 6% within the corticotroph adenoma. No increase in serum growth hormone or adrenocorticotropic hormone was found, indicating a clinically silent double adenoma. While transsphenoidal surgery remains a first-line approach for silent adenomas presenting with mass effects, increased rates of proliferative markers, such as the K i -67 index, provide useful insight into the clinical course of such tumors. Determining the K i -67 index of silent pituitary adenomas could be valuable in predicting recurrence after initial surgical resection and identifying tumors that are at an increased risk of needing additional therapeutic interventions or more frequent surveillance imaging.
Keywords: K i -67; corticotroph; double pituitary adenoma; somatotroph.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
Conflict of interest statement
Conflict of Interest None declared.
Figures



Similar articles
-
Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.Endocr Pathol. 2018 Dec;29(4):332-338. doi: 10.1007/s12022-018-9545-4. Endocr Pathol. 2018. PMID: 30215160
-
Composite somatotroph--ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma.Pituitary. 2001 Sep;4(4):215-21. doi: 10.1023/a:1020764013137. Pituitary. 2001. PMID: 12501971
-
Sparsely Granulated Corticotroph Pituitary Macroadenoma Presenting With Pituitary Apoplexy Resulting in Remission of Hypercortisolism.AACE Clin Case Rep. 2022 Apr 8;8(4):166-170. doi: 10.1016/j.aace.2022.04.003. eCollection 2022 Jul-Aug. AACE Clin Case Rep. 2022. PMID: 35959088 Free PMC article.
-
Subclinical hyperfunctioning pituitary adenomas: the silent tumors.Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):447-60. doi: 10.1016/j.beem.2012.01.002. Epub 2012 May 22. Best Pract Res Clin Endocrinol Metab. 2012. PMID: 22863387 Free PMC article. Review.
-
[Technical aspects and surgical strategy for removal of corticotroph pituitary adenoma].Neurochirurgie. 2002 May;48(2-3 Pt 2):186-214. Neurochirurgie. 2002. PMID: 12058125 Review. French.
Cited by
-
Double PitNETs: A Case Report and Literature Review.Cancers (Basel). 2025 Feb 17;17(4):675. doi: 10.3390/cancers17040675. Cancers (Basel). 2025. PMID: 40002269 Free PMC article. Review.
-
Double pituitary neuroendocrine tumors in a patient with normal growth hormone level acromegaly: A case report and review of the literature.Surg Neurol Int. 2023 Dec 15;14:425. doi: 10.25259/SNI_718_2023. eCollection 2023. Surg Neurol Int. 2023. PMID: 38213454 Free PMC article.
References
-
- Mayson S E, Snyder P J. Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol. 2014;117(03):429–436. - PubMed
-
- Larkin S, Ansorge O.Pathology and Pathogenesis of Pituitary Adenomas and Other Sellar LesionsPubMed; 2000. Accessed November 11, 2021 at:https://www.ncbi.nlm.nih.gov/books/NBK425704/
-
- Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(06):724–763. - PubMed
Publication types
LinkOut - more resources
Full Text Sources